Vaccines
Carrico J, Talbird SE, Eiden A, Carias C, Huang M, Lang JC, Marshall GS, Bencina G. Direct impact of pediatric immunization on reduction in antibiotic prescribing in the United States. Poster presented at the IDWeek 2024; October 17, 2024. Los Angeles, CA.
Poulos C, Marcek T, Chintakayala P, Boeri M, Francis A, Langevin E, Petigara T, O'Connor J, Samant S. Preferences of nurses in the United Kingdom for attributes of pediatric hexavalent vaccines: a discrete-choice experiment. Expert Rev Pharmacoecon Outcomes Res. 2025 Apr;25(4):543-50. doi: 10.1080/14737167.2025.2450352
BACKGROUND: We evaluated UK nurses’ preferences for pediatric hexavalent vaccine attributes.
Samant S, Oberle S, Marcek T, Poulos C, Chintakayala P, Langevin E, Petigara T, Boeri M. Preferences of healthcare providers in Switzerland for attributes of pediatric hexavalent vaccines: a discrete-choice experiment. Curr Med Res Opin. 2024 May;40(5):893-904. doi: 10.1080/03007995.2024.2325550
OBJECTIVE: To understand the preferences of healthcare providers (HCPs) in Switzerland for pediatric hexavalent vaccine attributes.
Poulos C, McMichael A, Kent C, Rudin D, Buck P, Ghaswalla P, Mehta D. Preferences for a combination influenza and COVID-19 vaccine: results from a threshold technique study with consumers in the United Kingdom. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S329. doi: 10.1016/j.jval.2024.03.2055
OBJECTIVES: To quantify preferences for a combination vaccine for influenza and coronavirus 2019 (COVID-19) compared with an influenza mono-vaccine among consumers in the United Kingdom (UK).
La E, Sweeney C, Davenport E, Bunniran S. Patient experiences with respiratory syncytial virus vaccination during the first season of vaccine availability: results from a survey of recently vaccinated older adults in the United States. Poster presented at the 2024 Virtual Annual Conference on Vaccinology Research; May 8, 2024. Virtual.
La E, Sweeney C, Davenport E, Bunniran S. Pharmacies as convenient adult vaccination settings in the United States: patient experiences from a survey of recently vaccinated adults. Poster presented at the 2024 Virtual Annual Conference on Vaccinology Research; May 8, 2024. Virtual.
La E, Singer D, Graham J, Grace M, Molnar D. Modeled public health impact of increasing respiratory syncytial virus vaccination coverage among adults Aged ≥ 60 years in the United States. Poster presented at the 2024 Virtual Annual Conference on Vaccinology Research; May 8, 2024.
George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 May;8(3):481-92. doi: 10.1007/s41669-024-00483-w
OBJECTIVES: The aim of this study was to update previously estimated public health impact and cost effectiveness of recombinant zoster vaccine (RZV) for the prevention of herpes zoster (HZ) in Canadians aged ≥50 years using longer-term RZV efficacy and waning data and real-world coverage and completion.